Immunovant director sells 1,500 shares, exercises options

Immunovant director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction.

Rhea-AI Filing Summary

Immunovant director Atul Pande exercised stock options and sold shares in a routine, pre-planned transaction. On the same day, he exercised options to acquire 1,500 shares of Common Stock at $8.43 per share and sold 1,500 shares in an open-market transaction at $34.02 per share.

The filing shows he continues to hold 116,731 Common Stock shares directly and 20,000 shares indirectly through a trust, as well as 69,681 remaining stock options after the exercise. The transactions were carried out under a Rule 10b5-1 trading plan adopted on December 26, 2025, indicating they were pre-scheduled rather than discretionary.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,500 shares ($38K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Pande Atul

Role Director

Sold 1,500 shs ($51K)

Approx. gross sale proceeds $51K

Approx. exercise cost $13K

Approx. pre-tax spread $38K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	1,500	$0.00	$0.00
Exercise	Common Stock	1,500	$8.43	$13K
Sale	Common Stock	1,500	$34.02	$51K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 69,681 contracts (Direct); Common Stock — 116,731 shares (Direct); Common Stock — 20,000 shares (Indirect, By Trust)

Footnotes (3)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
2. F2. Reflects an award of stock options to purchase Common Shares that is fully vested.
3. F3. The Form 4 filed on May 20, 2026 inadvertently disclosed the total of all remaining options held by the Reporting Person following the reported transaction in this specific option. This total correctly reflects only the remaining options for the specific option.

Key Figures

Shares sold: 1,500 shares Sale price: $34.02/share Options exercised: 1,500 shares +4 more

7 metrics

Shares sold 1,500 shares Common Stock sold at $34.02 per share on June 15, 2026

Sale price $34.02/share Open-market sale of 1,500 Common Stock shares

Options exercised 1,500 shares Stock options exercised at $8.43 per share

Exercise price $8.43/share Stock Option (right to buy) for Common Stock

Direct holdings after 116,731 shares Common Stock directly owned following transactions

Indirect holdings after 20,000 shares Common Stock held indirectly by trust

Remaining options 69,681 options Stock Option (right to buy) remaining after 1,500 exercised

Key Terms

Rule 10b5-1 Plan, stock options, Stock Option (right to buy), open-market sale, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

stock options financial

"Reflects an award of stock options to purchase Common Shares that is fully vested"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 8.4300"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"direct_or_indirect": "I", "nature_of_ownership": "By Trust""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immunovant (IMVT) director Atul Pande report in this Form 4?

Director Atul Pande reported exercising options for 1,500 Immunovant shares at $8.43 and selling 1,500 shares at $34.02. The filing also updates his remaining direct, indirect, and option holdings.

How many Immunovant (IMVT) shares did Atul Pande sell and at what price?

He sold 1,500 shares of Immunovant Common Stock at $34.02 per share. This open-market sale occurred on the same date as his related option exercise and was executed under a Rule 10b5-1 trading plan.

What stock options did Atul Pande exercise in Immunovant (IMVT)?

He exercised stock options covering 1,500 Immunovant Common Stock shares at an exercise price of $8.43 per share. The options are fully vested and relate to a grant expiring on November 19, 2029.

What are Atul Pande’s remaining Immunovant (IMVT) holdings after these transactions?

After the reported transactions, he holds 116,731 Immunovant Common Stock shares directly and 20,000 shares indirectly through a trust. He also has 69,681 stock options remaining from the specific option grant described.

Was Atul Pande’s Immunovant (IMVT) share sale part of a Rule 10b5-1 plan?

Yes. The filing states the reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on December 26, 2025. Such plans pre-schedule trades, making their timing less discretionary.

Did this Form 4 correct any prior disclosure about Immunovant (IMVT) options?

Yes. It notes a prior Form 4 on May 20, 2026 overstated remaining options by including all options. The updated figure, 69,681 options, reflects only the remaining options for this specific grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pande Atul

(Last) (First) (Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M(1)		1,500	A	$8.43	118,231	D
Common Stock	06/15/2026		S(1)		1,500	D	$34.02	116,731	D
Common Stock								20,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.43	06/15/2026		M(1)			1,500	(2)	11/19/2029	Common Stock	1,500	$0	69,681(3)	D

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.

2. Reflects an award of stock options to purchase Common Shares that is fully vested.

3. The Form 4 filed on May 20, 2026 inadvertently disclosed the total of all remaining options held by the Reporting Person following the reported transaction in this specific option. This total correctly reflects only the remaining options for the specific option.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Atul Pande	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)